FV MAR Targeted Therapies in Severe Asthma


How is the performance of medical affairs impacting prescribing for severe asthma brands in the US?
Clinicians treating severe asthma need the ongoing support of medical affairs teams to ensure complete knowledge of a product’s clinical value, status and use. The quality of medical affairs teams’ response and interaction is critical in supporting prescribing and treatment decisions, so how do front-line physicians rate the service they get and where do they see room for improvement? These and other key questions are answered in this insightful May 2019 analysis of 5 leading severe asthma biologic brands. Based on the results of an in-depth survey of 100 US-based allergists and pulmonologists, Medical Affairs Reputations (US) Targeted Therapies in Severe Asthma (Biologics) identifies the drivers and services that build clinician satisfaction and brand loyalty.
First Name*
Last Name*
Email*
Job Title*
Phone
Company Name
Country Name
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID